Both are approved for chronic weight management and both contain a GLP-1 receptor agonist, but they are different molecules given on different schedules. Saxenda is liraglutide and is injected daily. Wegovy is semaglutide and is injected weekly. For most people the practical difference that matters is the injection frequency.
For how this fits alongside the other comparisons, and what actually decides the choice, see Comparing GLP-1 Medications: How to Actually Choose.
Daily versus weekly
A daily injection is a different commitment from a weekly one, and it is the reason many people prefer the newer agents.
Daily dosing does have one advantage worth knowing: if a dose does not suit you, the effect is shorter-lived than with a weekly drug that stays in your system for days. That matters more for people who are cautious about tolerability or who have had difficulty with weekly agents.
It also means missing one dose is less disruptive than missing a weekly one.
The molecules
Liraglutide is an earlier GLP-1 receptor agonist. Semaglutide is a later one with a longer duration of action, which is what allows weekly dosing.
Both act on the same receptor and share the same broad side effect profile: nausea, vomiting, diarrhea, constipation, reflux.
Both carry the boxed warning about thyroid C-cell tumours and the same contraindications regarding medullary thyroid carcinoma and MEN2.
Where Saxenda still gets used
Availability and cost sometimes favour it. Formulary preferences vary, and a plan may cover one and not the other.
Approved age ranges differ between products in this class, which is relevant for adolescent prescribing. Check the current prescribing information rather than assuming.
Some prescribers use a daily agent where finer control over tolerability is wanted.
Titration
Both are titrated upward over weeks. The schedules differ, and both exist for the same reason: starting at a full dose would be intolerable for most people.
Side effects flare after each increase and settle with time at a dose, in the same pattern for both.
Coverage
Both are weight management products, which means both face the same structural problem: anti-obesity medication is an optional benefit that many plans exclude.
Where coverage exists, plans often prefer one, and step therapy requiring you to try the preferred agent first is common. Check your formulary before the conversation.
Switching
Moving between them means re-titrating and a new prior authorization under separate criteria. There is no simple dose equivalence, and where you start is a prescriber decision.
Do not take both in the same period.
Both face the same structural problem: anti-obesity medication is an optional benefit many plans exclude, as employer exclusions explains. Switching between them means re-titration and a fresh prior authorization.
Frequently asked questions
Is weekly better than daily?
More convenient for most people. Daily gives finer control if tolerability is a concern.
Which produces more weight loss?
A question for your prescriber against your situation, and not one that cross-trial comparison answers reliably.
Are the side effects the same?
Broadly similar, since both act on the same receptor.
Can I switch from daily to weekly?
Yes, with re-titration and a new authorization.
Do they have the same warnings?
The serious warnings are closely similar. Check the prescribing information for your product.
Is one cheaper?
Depends on your coverage and channel. Check rather than assume.